Nucleosides and emerging viruses: A new story - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Drug Discovery Today Année : 2022

Nucleosides and emerging viruses: A new story

Vincent Roy

Résumé

With several US Food and Drug Administration (FDA)-approved drugs and high barriers to resistance, nucleoside and nucleotide analogs remain the cornerstone of antiviral therapies for not only herpesviruses, but also HIV and hepatitis viruses (B and C); however, with the exception of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), for which vaccines have been developed at unprecedented speed, there are no vaccines or small antivirals yet available for (re)emerging viruses, which are primarily RNA viruses. Thus, herein, we present an overview of ribonucleoside analogs recently developed and acting as inhibitors of the viral RNA-dependent RNA polymerase (RdRp). They are new lead structures that will be exploited for the discovery of new antiviral nucleosides.

Dates et versions

hal-03859490 , version 1 (18-11-2022)

Identifiants

Citer

Vincent Roy, Luigi Agrofoglio. Nucleosides and emerging viruses: A new story. Drug Discovery Today, 2022, 27 (7), pp.1945-1953. ⟨10.1016/j.drudis.2022.02.013⟩. ⟨hal-03859490⟩
15 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More